NCT01195636已完成2 期
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Systemic Exposure of Topical XPF-002 in Subjects With Postherpetic Neuralgia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
- 主要终点
- Change in Mean Daily Pain Score From Baseline to Week 3 (With LOCF)
研究概览
简要总结
The purpose of this trial is to determine if XPF-002 is safe and effective for the treatment of pain in subjects with Postherpetic Neuralgia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 80 years (inclusive);
- •Males or females of non-childbearing potential (ie, 12 months or more of spontaneous amenorrhea, bilateral oophorectomy at least 6 months prior to randomization, hysterectomy with bilateral oophorectomy at least 6 months prior to randomization, or for females over 50 years of age, hysterectomy without bilateral oophorectomy at least 6 months prior to randomization);
- •Male subjects with sexual partners of childbearing potential must agree to use contraception (abstinence, birth control pills, rings or patches, diaphragm and spermicide, intrauterine device, condom and vaginal spermicide, surgical sterilization, vasectomy, progestin implant or injection);
- •Persistent pain for more than 6 months from the appearance of herpes zoster rash that is not located on the face, above the scalp hairline, or in proximity to mucous membranes;
- •Diagnosis of PHN;
- •Persistent neuropathic pain that involves at least 1 dermatome and covering no more than 400 cm2;
- •Mean daily pain intensity score in the target area of greater than or equal to 4 on an 11-point Likert NRS for a minimum of 4 days during the single-blind, placebo run-in period;
- •Subject agrees to take only the protocol-defined rescue medication as prescribed;
- •Intact skin over the painful area to be treated; and
- •Able and willing to provide informed consent and comply with study procedures.
排除标准
- •Subject with systemic disease that would put him/her at an additional risk or limit his/her ability to participate in the study in the opinion of the investigator;
- •Creatinine clearance less than 30 mL/min;
- •Subject with known history of human immunodeficiency virus, hepatitis C, or hepatitis B;
- •Malignancy other than basal cell carcinoma and carcinoma in situ within the past 2 years;
- •Subject with history of serious mental illness or psychiatric illness such as dementia, depression, or schizophrenia, that will limit his/her ability to comply with study procedures;
- •Subject who is unable to apply, or have a care giver apply, study ointment to the area of most painful skin segments, BID, once within 2 hours of waking and once in the evening after dinner;
- •Subject with known sensitivity to topical products;
- •Subject with active herpes zoster lesions or dermatitis;
- •Other severe or chronic pain that may impair the self-assessment of the pain due to PHN;
- •Treatment with local anesthetic in the last 2 weeks or nerve blocks within the last 30 days;
- •Subject who is taking any opioid medications to treat his/her PHN pain and is unable to washout of these medications for the duration of the study;
- •Subject who is taking any prohibited medication and is unable to washout of these treatments for the duration of the study;
- •Subject who is taking more than 2 permitted concomitant medications for the treatment of PHN and is unable to washout of all but 2 of these treatments for the duration of the study;
- •Subject who is taking any local prescription or non-prescription therapy (lidocaine patch, transcutaneous electrical nerve stimulation, etc.) and is unable to washout of these treatments for the duration of the study;
- •Subject who has used Qutenza® patches in the 90 days prior to screening or has used other capsaicin preparations on a daily basis in the 90 days prior to screening;
- •Subject who has participated in more than 1 other topical study for pain and more than 3 other PHN clinical studies;
- •Pregnant or lactating females;
- •Subject who has an active history of alcohol or drug abuse;
- •Subject who has participated in any other investigational study within 60 days prior to screening;
- •Subject who is employed by the Sponsor, study staff, and their families; or
- •Subject who has any condition that would make him/her, in the opinion of the investigator or Sponsor, unsuitable for the study.
研究组 & 干预措施
XPF-002
Experimental
干预措施: XPF-002 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Mean Daily Pain Score From Baseline to Week 3 (With LOCF)
时间窗: 3 weeks
Subjects recorded their pain scores 4 times each day (using an 11-point Likert numerical rating scale (NRS); 0-10, where 0 = no pain and 10 = worst pain imaginable). An average (mean) daily pain score was calculated. This measurement is the 'Change in mean daily pain score from baseline between the 3rd week of XPF-002 treatment and the 3rd week of placebo treatment for each subject'. Any missing mean daily pain scores were imputed using last observation carried forward (LOCF). The reduction in pain on each treatment compared to baseline is reported as a negative number. A larger negative number, indicates a greater reduction in pain. (A positive number would indicate pain was increased compared to baseline.)
次要结局
- Change in Mean Daily Pain Score From Baseline to Week 1(1 week)
- Proportion of Subjects Achieving at Least a 1 Point Improvement in Mean Daily Pain Score (Measured Using the 11-point Likert NRS) From Baseline to Week 3 on XPF-002 Compared to Placebo(3 Weeks)
- Proportion of Subjects Achieving 50% Improvement in Mean Daily Pain Score From Baseline to Week 3 on XPF-002 Treatment Compared to Placebo Treatment(3 weeks)
- Change in Overall Neuropathic Pain Symptom Inventory (NPSI) From Baseline to Week 3 (With LOCF)(3 Weeks)
- Change in Mean Daily Pain Score From Baseline to Week 2(2 week)
- Proportion of Subjects Using Rescue Analgesic Medications During XPF-002 Treatment Compared to Placebo Treatment(3 Weeks)
- Change in Daily Sleep Interference Scale (DSIS) From Baseline to Week 3 of XPF-002 Treatment Compared to Week 3 of Placebo Treatment (With LOCF)(3 Weeks)
- Change in Mean Daily Pain Score From Baseline to Week 3(3 Weeks)
- Proportion of Subjects Achieving 30% Improvement in Mean Daily Pain Score From Baseline to Week 3 on XPF-002 Treatment Compared to Placebo Treatment(3 Weeks)
研究者
相似试验
已完成
2 期
Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth ExtractionDental PainNCT00954356Xenon Pharmaceuticals Inc.61
已完成
3 期
Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the KneeOsteoarthritis of the KneeNCT02357459Pacira Pharmaceuticals, Inc486
已完成
2 期
A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following BunionectomyAcute PainNCT03764072Vertex Pharmaceuticals Incorporated250
已完成
2 期
Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal SurgeryPost-Operative PainNCT02489526Vivozon, Inc.60
已完成
2 期
Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following GastrectomyPost-Operative PainNCT02844725Vivozon, Inc.60